Professor Del Galdo, Workstream 3 lead for Musculoskeletal Disease at NIHR Leeds Biomedical Research Centre (BRC), has collaborated with experts across Europe and the Middle East to establish comprehensive, evidence-based guidance for the treatment and management of systemic sclerosis (SSc).
These new guidelines, developed under the European Alliance of Associations for Rheumatology (EULAR), provide detailed recommendations for healthcare providers and patients on the best practices for managing this rare and complex disease.
Systemic sclerosis, or scleroderma, is a rare connective tissue disorder with autoimmune and vascular components that can lead to tissue fibrosis or scarring in the skin and organs. The disease often presents with Raynaud’s phenomenon—where blood flow to extremities like the fingers and toes decreases, leading to cold-induced color changes—as well as other potentially severe symptoms, such as digital ulcers, pulmonary arterial hypertension, and scleroderma renal crisis. Each of these manifestations requires tailored treatment, which the EULAR guidelines address in detail.
With 22 recommendations covering eight primary organ systems affected by SSc, including skin, lungs, gastrointestinal tract, and joints, the guidelines provide a roadmap for medical professionals to manage both common and complex complications of the disease. The recommendations also address the needs of individuals with severe prognoses, offering direction for cases that present with multiple or particularly aggressive symptoms.
Prof. Del Galdo noted that these guidelines are designed not only to assist medical professionals in delivering informed, effective care but also to empower patients with a deeper understanding of their condition and treatment options.
For the complete guidelines and recommendations, visit the EULAR website.